Silibinin A decreases statin‑induced PCSK9 expression in human hepatoblastoma HepG2 cells-Reference-Cited by-同舟云学术

Silibinin A decreases statin‑induced PCSK9 expression in human hepatoblastoma HepG2 cells

Published:2019-06-05 Issue: Volume: Page:
ISSN:1791-2997
Container-title:Molecular Medicine Reports
language:
Short-container-title:Mol Med Report

Author:

Dong Zhewen¹,Zhang Wenxiang²,Chen Siyu²,Liu Chang¹

Affiliation:

1. Jiangsu Key Laboratory for Molecular Medical Biotechnology and School of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu 210023, P.R. China

2. State Key Laboratory of Natural Medicines and School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu 211198, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,Genetics,Molecular Biology,Molecular Medicine,Biochemistry

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chenodeoxycholic Acid‐Modified Polyethyleneimine Nano‐Composites Deliver Low‐Density Lipoprotein Receptor Genes for Lipid‐Lowering Therapy by Targeting the Liver;Advanced Healthcare Materials;2024-06-16

2. Inhibitory Effect of KIOM-2015EW, a Water Extract of Acer Palmatum Thumb, on PCSK9 Expression in a Fructose-Induced in Vitro Fatty Liver Model;J BIOL REG HOMEOS AG;2024

3. Schisandrin A in Schisandra chinensis Upregulates the LDL Receptor by Inhibiting PCSK9 Protein Stabilization in Steatotic Model;Journal of Microbiology and Biotechnology;2023-10-31

4. Natural Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Review;Combinatorial Chemistry & High Throughput Screening;2023-09

5. PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity;Cells;2022-12-19